Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Database
Language
Publication year range
1.
Cancer Discov ; 2024 Jun 25.
Article in English | MEDLINE | ID: mdl-38922581

ABSTRACT

Comprehensive m6A epitranscriptome profiling of primary tumors remains largely uncharted. Here, we profiled the m6A epitranscriptome of 10 non-neoplastic lung (NL) tissues and 51 lung adenocarcinoma (LUAD) tumors, integrating the corresponding transcriptome, proteome and extensive clinical annotations. We identified distinct clusters and genes that were exclusively linked to disease progression through m6A modifications. In comparison with NL tissues, we identified 430 transcripts to be hypo-methylated and 222 to be hyper-methylated in tumors. Among these genes, EML4 emerged as a novel metastatic driver, displaying significant hyper-methylation in tumors. m6A modification promoted the translation of EML4, leading to its widespread overexpression in primary tumors. Functionally, EML4 modulated cytoskeleton dynamics through interacting with ARPC1A, enhancing lamellipodia formation, cellular motility, local invasion, and metastasis. Clinically, high EML4 protein abundance correlated with features of metastasis. METTL3 small molecule inhibitor markedly diminished both EML4 m6A and protein abundance, and efficiently suppressed lung metastases in vivo.

2.
Nat Commun ; 13(1): 6467, 2022 10 29.
Article in English | MEDLINE | ID: mdl-36309516

ABSTRACT

Metastatic prostate cancer remains a major clinical challenge and metastatic lesions are highly heterogeneous and difficult to biopsy. Liquid biopsy provides opportunities to gain insights into the underlying biology. Here, using the highly sensitive enrichment-based sequencing technology, we provide analysis of 60 and 175 plasma DNA methylomes from patients with localized and metastatic prostate cancer, respectively. We show that the cell-free DNA methylome can capture variations beyond the tumor. A global hypermethylation in metastatic samples is observed, coupled with hypomethylation in the pericentromeric regions. Hypermethylation at the promoter of a glucocorticoid receptor gene NR3C1 is associated with a decreased immune signature. The cell-free DNA methylome is reflective of clinical outcomes and can distinguish different disease types with 0.989 prediction accuracy. Finally, we show the ability of predicting copy number alterations from the data, providing opportunities for joint genetic and epigenetic analysis on limited biological samples.


Subject(s)
Cell-Free Nucleic Acids , Prostatic Neoplasms , Male , Humans , Epigenome , Cell-Free Nucleic Acids/genetics , Prostatic Neoplasms/pathology , Prostate/pathology , DNA Methylation/genetics
3.
Front Neurosci ; 13: 390, 2019.
Article in English | MEDLINE | ID: mdl-31191209

ABSTRACT

A robust adaptive recurrent cerebellar model articulation controller (RARC) neural network for non-linear systems using the genetic particle swarm optimization (GPSO) algorithm is presented in this study. The RARC is used as the principal tracking controller and the robust compensation controller is designed to recover the residual of the approximation error. In the RARC neural network, the steepest descent gradient method and the Lyapunov function are used for deriving the adaptive law parameter of the system. Besides, the learning rates play an important role in these adaptive laws and they have a great effect on the functions of control systems. In this paper, the combination of the genetic algorithm with the mutation particle swarm optimization algorithm is applied to seek for the optimal learning rates of the RARC adaptation laws. The numerical simulations about the inverted pendulum system as well as the robot manipulator system are given to confirm the effectiveness and practicability of the GPSO-RARC-based control system. Compared with other control schemes, the proposed control scheme is testified to be reliable and can obtain the optimal parameter about the learning rates and the minimum root mean square error for non-linear systems.

4.
Cell ; 176(4): 831-843.e22, 2019 02 07.
Article in English | MEDLINE | ID: mdl-30735634

ABSTRACT

The cancer transcriptome is remarkably complex, including low-abundance transcripts, many not polyadenylated. To fully characterize the transcriptome of localized prostate cancer, we performed ultra-deep total RNA-seq on 144 tumors with rich clinical annotation. This revealed a linear transcriptomic subtype associated with the aggressive intraductal carcinoma sub-histology and a fusion profile that differentiates localized from metastatic disease. Analysis of back-splicing events showed widespread RNA circularization, with the average tumor expressing 7,232 circular RNAs (circRNAs). The degree of circRNA production was correlated to disease progression in multiple patient cohorts. Loss-of-function screening identified 11.3% of highly abundant circRNAs as essential for cell proliferation; for ∼90% of these, their parental linear transcripts were not essential. Individual circRNAs can have distinct functions, with circCSNK1G3 promoting cell growth by interacting with miR-181. These data advocate for adoption of ultra-deep RNA-seq without poly-A selection to interrogate both linear and circular transcriptomes.


Subject(s)
Prostatic Neoplasms/genetics , RNA/genetics , RNA/metabolism , Gene Expression Profiling/methods , Genetic Profile , HEK293 Cells , Humans , Male , MicroRNAs/metabolism , Prostate/metabolism , RNA Splicing/genetics , RNA, Circular , RNA, Untranslated/genetics , Sequence Analysis, RNA/methods , Transcriptome
5.
PLoS Biol ; 16(9): e2006092, 2018 09.
Article in English | MEDLINE | ID: mdl-30212448

ABSTRACT

N6-Methyladenosine (m6A) accounts for approximately 0.2% to 0.6% of all adenosine in mammalian mRNA, representing the most abundant internal mRNA modifications. m6A RNA immunoprecipitation followed by high-throughput sequencing (MeRIP-seq) is a powerful technique to map the m6A location transcriptome-wide. However, this method typically requires 300 µg of total RNA, which limits its application to patient tumors. In this study, we present a refined m6A MeRIP-seq protocol and analysis pipeline that can be applied to profile low-input RNA samples from patient tumors. We optimized the key parameters of m6A MeRIP-seq, including the starting amount of RNA, RNA fragmentation, antibody selection, MeRIP washing/elution conditions, methods for RNA library construction, and the bioinformatics analysis pipeline. With the optimized immunoprecipitation (IP) conditions and a postamplification rRNA depletion strategy, we were able to profile the m6A epitranscriptome using 500 ng of total RNA. We identified approximately 12,000 m6A peaks with a high signal-to-noise (S/N) ratio from 2 lung adenocarcinoma (ADC) patient tumors. Through integrative analysis of the transcriptome, m6A epitranscriptome, and proteome data in the same patient tumors, we identified dynamics at the m6A level that account for the discordance between mRNA and protein levels in these tumors. The refined m6A MeRIP-seq method is suitable for m6A epitranscriptome profiling in a limited amount of patient tumors, setting the ground for unraveling the dynamics of the m6A epitranscriptome and the underlying mechanisms in clinical settings.


Subject(s)
Gene Expression Profiling , Immunoprecipitation/methods , RNA/metabolism , A549 Cells , Adenocarcinoma of Lung/genetics , Adenocarcinoma of Lung/pathology , Adenosine/analogs & derivatives , Adenosine/metabolism , Antibodies/metabolism , Base Sequence , Humans , RNA/genetics
SELECTION OF CITATIONS
SEARCH DETAIL
...